60 likes | 164 Views
Summary of PK studies thru 10/1/04*. * Samples analyzed thru 5/30/04. Immunosuppressant doses and Cmin after 2-4 weeks of rx. 350. 300. Wk 2. Wk 12. Wk 28. Yr 1. Yr 2. 250. 200. 150. CsA mg/dose. 100. 50. 0. NVP. EFV. 1 PI. 2 PI. kaletra. NNRTI. NNRTI +. +PI . kaletra.
E N D
Summary of PK studies thru 10/1/04* * Samples analyzed thru 5/30/04
350 300 Wk 2 Wk 12 Wk 28 Yr 1 Yr 2 250 200 150 CsA mg/dose 100 50 0 NVP EFV 1 PI 2 PI kaletra NNRTI NNRTI + +PI kaletra CsA Dosing by ARV and week
300000 250000 200000 150000 LPV ng*h/mL 100000 50000 0 LPV LPV + NNRTI 7000 6000 5000 4000 RTV ng*h/mL 3000 2000 1000 0 RTV RTV + NNRTI efficacy pretx W2 W12 W28 Y1 Y2 Kaletra AUC by week
40000 35000 30000 25000 AUC ng*h/mL 20000 15000 10000 5000 0 NFV efficacy pretx NFV+NNRTI W2 W12 W28 Y1 60 M8 50 NFV 40 AUC mcg*h/mL 30 20 10 0 pretx 2 12 28 yr 1 yr 2 time NFV AUC by week M8/NFV AUC by week
100000 NVP AUC ng*h/mL efficacy pretx Wk 2 80000 Wk 12 Wk 28 Yr 1 Yr 2 60000 40000 NVP+ PI NVP 120000 20000 100000 80000 0 EFV AUC ng*h/mL 60000 40000 20000 0 EFV EFV + PI NNRTI AUC by week